Sugi Predict

Sugi Predict / Compounds / SCHEMBL22196882

SCHEMBL22196882

SCHEMBL22196882

CC(C)CCOCCNC(=O)CCl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ HPGD P15428 2/20 0.38
▸ TDP1 Q9NUW8 1/20 0.37
▸ CNR1 P21554 1/20 0.35
▸ CNR2 P34972 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ TEAD1 P28347 1/20 0.33
▸ YAP1 P46937 1/20 0.33
▸ TEAD4 Q15561 1/20 0.33
▸ TEAD2 Q15562 1/20 0.33
▸ LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25866786 0.89 KMT2A (0.50) KMT2AMEN1ALDH1A1SMN1; SMN2HPGD
SCHEMBL18855041 0.85 KMT2A (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2HPGD
SCHEMBL18866867 0.85 MEN1 (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2HPGD
SCHEMBL11912086 0.85 ALDH1A1 (0.50) KMT2AMEN1ALDH1A1HPGDTDP1
SCHEMBL17874808 0.85 MEN1 (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2HPGD
SCHEMBL25834703 0.85 MEN1 (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2HPGD
SCHEMBL11395098 0.84 SMN1; SMN2 (0.56) KMT2AMEN1ALDH1A1SMN1; SMN2TSHR
SCHEMBL23334288 0.84 MEN1 (0.50) KMT2AMEN1ALDH1A1SMN1; SMN2HPGD
SCHEMBL25118084 0.84 MEN1 (0.50) KMT2AMEN1ALDH1A1SMN1; SMN2HPGD
SCHEMBL25118082 0.84 KMT2A (0.50) KMT2AMEN1ALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023125751-A1 DIA-BASED QUANTITATIVE CHEMICAL PROTEOMICS TARGET SCREENING METHOD 北京大学 2023-07-06 — — WO disclosed
US-20220298213-A1 IN VIVO ENGINEERED CEREBLON PROTEIN VIVIDION THERAPEUTICS, INC. 2022-09-22 — — US disclosed
US-20210002337-A1 IN VIVO ENGINEERED CEREBLON PROTEIN THE SCRIPPS RESEARCH INSTITUTE 2021-01-07 — — US disclosed
US-10781239-B2 In vivo engineered cereblon protein VIVIDION THERAPEUTICS, INC. (US) 2020-09-22 — — US disclosed
US-20200216507-A1 IN VIVO ENGINEERED CEREBLON PROTEIN VIVIDION THERAPEUTICS, INC. 2020-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298213-A1 IN VIVO ENGINEERED CEREBLON PROTEIN CRBN, CDR2, DCUN1D4 KMT2A 607/4885MEN1 425/4885ALDH1A1 2798/4885
US-20200216507-A1 IN VIVO ENGINEERED CEREBLON PROTEIN CRBN, CDR2, DCUN1D4 KMT2A 607/4885MEN1 425/4885ALDH1A1 2798/4885
US-20210002337-A1 IN VIVO ENGINEERED CEREBLON PROTEIN CRBN, CDR2, DCUN1D4 KMT2A 607/4885MEN1 425/4885ALDH1A1 2798/4885
US-10781239-B2 In vivo engineered cereblon protein CRBN, CDR2, DCUN1D4 KMT2A 607/4885MEN1 425/4885ALDH1A1 2798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.